U.S. Chemical & Life Science Patents Q2 – 2026 Newsletter
TO READ THE LATEST ISSUE CLICK HERE
The latest edition of Harness IP’s Chemical & Life Science Newsletter explores the legal, regulatory, and patent developments impacting innovation across the chemical, pharmaceutical, biotechnology, and life sciences industries. Inside, you’ll find analysis of recent Supreme Court and Federal Circuit decisions, updates on new USPTO initiatives, practical patent drafting guidance, and the latest FDA recommendations for gene-editing technologies. Discover the insights and strategies helping innovators and IP professionals stay ahead in a rapidly evolving landscape.
WHAT’S INSIDE:
US Chemical & Life Sciences Case Law Updates
- Supreme Court Clarifies Induced Infringement Standard in Hikma v. Amarin
- Federal Circuit Finds “About” Claims Indefinite
- Federal Circuit Affirms Unlawful Patent Tying Decision
- Patent Invalidated Due to Uncorrectable Inventorship
- Federal Circuit Rejects Dismiss-and-Refile Litigation Strategy
USPTO Updates
- Fast-Track Appeals Pilot Extended Through 2028
- USPTO Launches PIER Pilot Program
- PTAB Awards CRISPR-Cas9 Priority to Broad Institute
- USPTO Confirms Government-Owned Entities Cannot File IPRs
- Updated SMED Best Practices Memorandum Issued
Other Updates
- FDA Releases Draft Guidance on Gene-Editing Safety Testing
- FDA Issues Guidance on Using Prior Data for Gene Therapy Approval
For more updates on Chemical and Life Science law read the previous CLS Newsletters here.